Skye Bioscience to Participate in May Investment and Medical Conferences
Rhea-AI Summary
Skye Bioscience (Nasdaq: SKYE), a clinical-stage biotech company specializing in obesity and metabolic health disorders, has announced its participation in multiple high-profile conferences this May.
The company will engage in two key investment conferences:
- Citizens Life Sciences Conference in New York (May 8) - Featuring a presentation at 11:00 am ET and one-on-one meetings
- Craig-Hallum Institutional Investor Conference in Minneapolis (May 28) - Offering one-on-one meeting opportunities
Additionally, Skye will present a scientific poster at the European Congress on Obesity in Malaga, Spain on May 13. Interested parties can access available webcasts through the company's website.
Positive
- Multiple high-profile conference presentations indicating strong institutional interest
- Clinical-stage biotech status with focus on large market (obesity and metabolic disorders)
- Nasdaq-listed company showing market validation
Negative
- None.
News Market Reaction
On the day this news was published, SKYE gained 4.71%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will participate in the following upcoming healthcare conferences:
Investment Conferences
- Citizens Life Sciences Conference (New York)
Presentation, Thursday, May 8, 11:00 am ET + 1x1 meetings
- Craig-Hallum Institutional Investor Conference (Minneapolis)
1x1 meetings, Wednesday, May 28
Medical Conference
- European Congress on Obesity (Malaga, Spain)
Poster presentation, May 13
Available webcasts will be accessible on Skye’s website.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTS
Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. These forward looking statements include, but are not limited to: (i) statements regarding the superior safety and tolerability profile of nimacimab relative to other small molecule CB1 inhibitors, (ii) statements relating to any expectations regarding the efficacy and therapeutic potential of nimacimab as a monotherapy or in combination with a GLP-1 targeted drug, including expectations based on preclinical DIO models, (iii) statements regarding nimacimab’s potential to change weight loss standards of care, (iv) statements regarding superior potency of nimacimab to other small molecule CB1 inhibitors based on nimacimab’s mechanism of action and (v) statements regarding the timing of receipt of final data from Skye’s Phase 2 obesity study of nimacimab. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company’s periodic filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Skye’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
FAQ
When is Skye Bioscience (SKYE) presenting at the Citizens Life Sciences Conference 2025?
Which medical conference will Skye Bioscience (SKYE) attend in May 2025?
What type of biotechnology does Skye Bioscience (SKYE) focus on?
Where can investors watch Skye Bioscience's (SKYE) conference presentations?
Which investor conferences is Skye Bioscience (SKYE) attending in May 2025?
